Inappropriate prescribing for osteoporosis

• 1 Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA.
• 2 SA Health Working Party on Prevention of Osteoporosis and Fractures, Adelaide, SA.
• 3 Department of Nuclear Medicine and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA.

---

• 1. Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 2003; 18: 1947-1954.
• 2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280: 2077-2082.
• 3. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000; 85: 4118-4124.
• 4. Abrahamsen B, Vestergaard P, Rud B, et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2006; 21: 796-800.
• 5. Access Economics. The burden of brittle bones: costing osteoporosis in Australia. Canberra: Access Economics for Osteoporosis Australia, 2001.
• 6. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297: 387-394.
• 7. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-532.